| FZAMX | VEXAX | FZAMX / VEXAX | |
| Total Expense Ratio | 0.58 | 0.05 | 1,160% |
| Annual Report Gross Expense Ratio | 0.58 | 0.05 | 1,160% |
| Fund Existence | 13 years | 26 years | - |
| Gain YTD | 20.867 | 13.061 | 160% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 3000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.29B | 97.7B | 2% |
| Annual Yield % from dividends | 0.28 | 1.03 | 27% |
| Returns for 1 year | 24.25 | 19.75 | 123% |
| Returns for 3 years | 36.51 | 51.91 | 70% |
| Returns for 5 years | 17.54 | 28.28 | 62% |
| Returns for 10 years | 62.66 | 175.82 | 36% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HPS | 14.22 | 0.03 | +0.21% |
| John Hancock Preferred Income Fund III | |||
| DEM | 53.70 | 0.10 | +0.19% |
| WisdomTree Emerging Markets High Div ETF | |||
| MYCI | 24.68 | -0.01 | -0.06% |
| State Street® My2029 Corporate Bond ETF | |||
| DVXP | 25.85 | -0.12 | -0.45% |
| WEBs Consumer Staples XLP Dfnd Vol ETF | |||
| BIB | 96.61 | -3.71 | -3.70% |
| ProShares Ultra Nasdaq Biotechnology | |||